Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who have been diagnosed with one of the following cancer types, confirmed by laboratory testing of tissue or cell samples: breast, stomach, kidney, prostate, lung (including both main types), liver, colorectal, head and neck, thyroid, pancreatic, ovarian, glioblastoma (a type of brain cancer), endometrial (uterine lining), bladder, superficial oesophago-gastric (food pipe/stomach junction), or diffuse large B-cell lymphoma.
• People who have signed a written consent form agreeing to take part in the study.
• People who are covered by a social insurance scheme (confirm with trial site regarding what qualifies).
• People whose doctor has recommended a treatment plan aimed at curing the cancer, including options such as surgery, radiotherapy, chemotherapy, hormone therapy, or targeted treatments.
• People whose doctor has recommended a treatment plan that is not aimed at a cure, such as chemotherapy, hormone therapy, immunotherapy, targeted treatments, or non-curative surgery.
• People who have not previously received anti-cancer treatment for the cancer in question (with some exceptions — see below).
• People who previously received treatment with curative intent, provided that treatment did not include systemic chemotherapy, and a complete remission lasting at least 6 months was observed before any relapse.
• People who previously received local treatment for superficial lesions (for example, bladder-directed treatment for superficial bladder cancer), with no time restriction on when that treatment occurred.

Cancer-type specific criteria that also apply:

• Breast cancer: People with invasive ductal or invasive lobular breast carcinoma; those in the curative group must be planned for surgery, with or without chemotherapy and/or hormone treatment.
• Stomach cancer: People with intestinal-type or diffuse-type stomach adenocarcinoma; those in the curative group must be planned for surgery, with or without additional treatments.
• Kidney cancer: People with any type of kidney cancer, including non-clear cell types; a tissue biopsy is not always required if imaging shows typical signs of kidney cancer; those in the curative group must be planned for partial or full kidney removal surgery.
• Prostate cancer (curative group): People with localised high-risk prostate cancer meeting specific staging and scoring criteria (confirm with trial site), planned for radical prostatectomy or radiotherapy, possibly with hormone-suppression therapy; brachytherapy and focused ultrasound are not allowed.
• Prostate cancer (non-curative group): People with metastatic castration-resistant prostate cancer meeting recognised diagnostic criteria, planned to be treated with docetaxel, cabazitaxel, abiraterone, or enzalutamide, and who have not yet received treatment specifically for castration-resistant disease; people who previously received docetaxel or hormone therapy for hormone-sensitive metastatic prostate cancer may still be eligible.
• Lung cancer treated with immunotherapy (non-curative group): People with stage IV non-small cell lung cancer (NSCLC) planned to receive immunotherapy, with or without chemotherapy.
• Lung cancer not treated with immunotherapy (curative group): People with NSCLC at stage I, II, IIIA, or IIIB, planned for surgery or radiotherapy with or without chemotherapy; immunotherapy is not included in this group.
• Lung cancer not treated with immunotherapy (non-curative group): People with stage IV NSCLC or small cell lung cancer (SCLC) planned for a first round of chemotherapy, with or without other treatments (excluding immunotherapy at this stage; immunotherapy may be used in later treatment rounds).
• Liver cancer (hepatocellular carcinoma): A tissue biopsy is not always required if imaging shows typical signs; people must not have ongoing or treatment-resistant fluid build-up in the abdomen, or chronic confusion related to liver disease; curative group must be planned for surgical removal or specific ablation procedures (not liver transplantation); non-curative group must be planned for chemoembolisation, targeted therapy, or immunotherapy.
• Colorectal cancer (curative group): People with a specific type of bowel cancer that has spread, planned for chemotherapy with or without targeted treatment, and planned for surgery in between treatment rounds.
• Head and neck cancer: People with squamous cell carcinoma of the mouth, throat, voice box, or surrounding areas; curative group must be planned for surgery and/or radiotherapy, with or without chemotherapy; non-curative group must have newly spread or relapsed disease planned for chemotherapy and/or immunotherapy.
• Thyroid cancer (curative group): People with certain types of thyroid cancer for which radioactive iodine treatment is planned after surgery; people will be removed from the study if the final pathology results or post-surgery assessment shows iodine treatment is not needed or the diagnosis does not confirm high-risk thyroid cancer.
• Pancreatic cancer (curative group): People with exocrine pancreatic adenocarcinoma planned for surgery, with or without chemotherapy before or after.
• Ovarian cancer (non/uncertain curative group): People experiencing a first platinum-sensitive relapse of high or low grade ovarian adenocarcinoma or carcinosarcoma, planned for chemotherapy and/or PARP inhibitor treatment, with or without surgery.
• Glioblastoma (curative group): People planned for surgical removal followed by temozolomide chemotherapy and radiotherapy.
• Endometrial cancer (non-curative group): People with type 1 or type 2 endometrial cancer with advanced or metastatic disease, planned for non-curative systemic treatment.
• Bladder cancer (curative group): People with muscle-invasive transitional cell bladder cancer, planned for cisplatin-based chemotherapy, immunotherapy, or a combination of both before surgery.
• Superficial oesophago-gastric cancer (curative group): People with early-stage (T1) cancer of the food pipe or stomach junction, planned for endoscopic (internal camera-guided) surgery.
• Diffuse large B-cell lymphoma (curative group): People planned to receive a specific combination chemotherapy regimen known as R-CHOP.

Who may not be able to join:

• People under 18 years of age.
• People who have not signed a written consent form agreeing to participate.
• People not covered by a social insurance scheme (confirm with trial site).
• People in the curative group who have previously received systemic chemotherapy for the cancer in question, unless a complete remission of at least 6 months occurred after a prior curative-intent treatment that did not include systemic chemotherapy.
• People in the non-curative group who have already received anti-cancer treatment in a non-curative setting (with the exception of certain prostate cancer patients, as noted above).
• People with liver cancer who have chronic confusion caused by liver disease, or who have fluid build-up in the abdomen that does not respond to treatment.
• People with liver cancer in the curative group who are being considered for liver transplantation (this specific option is excluded from the curative group criteria).
• People with prostate cancer in the curative group planned to receive brachytherapy or focused ultrasound treatment.
• People with thyroid cancer whose post-surgery results show the diagnosis does not confirm high-risk thyroid cancer, or for whom iodine treatment is not recommended after surgery (these individuals would be withdrawn from the study).

Important: Always verify eligibility with the trial site directly before applying.